Lyell Immunopharma (LYEL) Net Cash Flow (2020 - 2026)
Lyell Immunopharma (LYEL) posted Net Cash Flow of $30.6 million for Q1 2026, up 148.25% sequentially from -$63.4 million in Q4 2025, and up 107.69% YoY from $14.7 million in Q1 2025.
Lyell Immunopharma (LYEL) Net Cash Flow (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Net Cash Flow for 7 years, with the latest figure at $30.6 million in Q1 2026.
- Quarterly Net Cash Flow rose 107.69% year-over-year to $30.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.7 million (down 656.63% YoY) and the FY2025 annual result came in at -$45.5 million, down 17.8% from the prior year.
- Net Cash Flow advanced to $30.6 million in Q1 2026 per LYEL's latest filing, from -$63.4 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $114.9 million in Q2 2023 and troughed at -$140.6 million in Q4 2023.
- A 5-year average of -$11.9 million and a median of -$14.1 million in 2023 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 781.89% in 2023, down 2040.45% in 2023.
- Over 5 years, Net Cash Flow stood at $7.2 million in 2022, then plunged by 2040.45% to -$140.6 million in 2023, then jumped by 104.77% to $6.7 million in 2024, then plunged by 1046.18% to -$63.4 million in 2025, then soared by 148.25% to $30.6 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $30.6 million, -$63.4 million, and $24.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -17.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.78 Mn |
| Jun 30, 2026 | -17.78 Mn |
| Mar 31, 2026 | 30.59 Mn |
| Mar 31, 2026 | 30.59 Mn |
| Dec 31, 2025 | -63.39 Mn |
| Dec 31, 2025 | -63.39 Mn |
| Sep 30, 2025 | 24.77 Mn |
| Sep 30, 2025 | 24.77 Mn |
| Jun 30, 2025 | -21.63 Mn |
| Jun 30, 2025 | -21.63 Mn |
| Mar 31, 2025 | 14.73 Mn |
| Mar 31, 2025 | 14.73 Mn |
| Dec 31, 2024 | 6.70 Mn |
| Dec 31, 2024 | 6.70 Mn |
| Sep 30, 2024 | -33.12 Mn |
| Sep 30, 2024 | -33.12 Mn |
| Jun 30, 2024 | 7.78 Mn |
| Jun 30, 2024 | 7.78 Mn |
| Mar 31, 2024 | -20.00 Mn |
| Mar 31, 2024 | -20.00 Mn |